Kurt Machemer Photo

Industry Experience

Kurt focuses his practice on meeting the business and legal needs of emerging growth companies in the life sciences and technology sectors, as well as venture capitalists and other investors in early stage companies. He represents organizations at various stages of development, including companies with marketed pharmaceutical products, medical devices/diagnostics, and various innovative drug development programs.

Kurt helps clients through a variety of complex transactions, including public and private offerings of equity and debt securities, acquisitions and dispositions of private companies, and joint ventures and other strategic partnerships. In addition, he regularly counsels entrepreneurs, senior management and boards of directors on pre-formation, formation, governance and transactional matters.  Kurt also counsels companies and senior executives on employment and separation matters. 

experience +

experience –

Prior to joining the firm, Kurt was an attorney with Gunderson Dettmer Stough Villeneuve Franklin & Hachigian, where his practice focused on representing corporate clients and venture capital firms. He began his legal career at Nutter McClennen & Fish.

Recent Client Work +

Recent Client WOrk –

  • Equity investments by .406 Ventures in multiple portfolio companies, including CloudPercept and Rapid Focus
  • Equity investment by Merck Research Laboratories in Alector
  • Acquisition of Partners Health System’s ownership stake in CoStim by Novartis
  • Equity investments by Third Rock Ventures in multiple portfolio companies including Blueprint Medicines, Constellation Pharmaceuticals, DC Devices, Edimer Pharmaceuticals, Eleven Biotherapeutics, NinePoint Medical, Nurix, Igenica Biotherapeutics, and Sage Therapeutics
  • ProThera Biologics’ strategic partnership with ProMetic Life Sciences
  • Structured acquisition by Techcomp (Holdings) Limited of IXRF Systems
  • Equity financing of Navitor Pharmaceuticals by Polaris Partners, Atlas Venture, Johnson & Johnson Innovation, S.R. One, Brace Pharma Capital, Remeditex Ventures, Sanofi-Genzyme BioVentures and others
  • Massachusetts Institute of Technology (MIT) in collaboration with the Skolkovo Foundation to create the Skolkovo Institute of Science and Technology outside Moscow, Russia
  • Equity investment by Biogen in Solid GT
  • Equity financing of Civitas Therapeutics and repayable grant from Michael J. Fox Foundation for Parkinson’s Research
  • Equity investments and flips to U.S.-based topcos by Accel Partners in multiple portfolio companies
  • Option agreement and equity financing of Siamab Therapeutics by Momenta Pharmaceuticals
  • Strategic equity investment by Biogen in Proteostasis Therapeutics
  • Equity investment by Lundbeckfond Ventures in Cydan Development
  • Sale of AesRx (with a Phase II sickle cell program) to Baxter International
  • Equity investment by Novo A/S in ZS Pharma
  • Spin-out and equity financing of Mellitus from Harvard Medical School
  • Equity investment by Balderton Capital and Notion Capital in Groupay
  • Purchase by Biogen of certain antibody assets from Amgen
  • Formation and corporate governance of TransPoC, a not-for-profit scientific research organization
  • Equity financing of Foundation Medicine by Google Ventures and Kleiner Perkins Caufield & Byers
  • Formation and financing of Unum Therapeutics

Community +

Community –

Bar Admissions
  • Massachusetts 
  • ‍Boston University School of Law, J.D.
  • University of Michigan, B.A.